A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Inclusion Criteria:

1. Participants must have a confirmed diagnosis of Stage IIIC, IIID, or IV unresectableor metastatic melanoma or Stage III or IV NSCLC.

2. Participants who have received the following previous therapy:

3. Cohort 1 (Melanoma): Participants who have progressed within 12 weeks of lastdose of anti-PD-1/PD-L1 blocking antibody and received BRAF/MEK inhibitor inthose with BRAF mutations.

4. Cohort 2 (NSCLC): Participants who should have received no more than 3 priorlines of therapy and:

• those without oncogene-driven tumors: Have progressed within 12 weeksafter last dose of anti-PD-1/PD-L1 blocking antibody
• those with oncogene-driven tumors: Have progressed during/after ≥1targeted therapy AND either:
• platinum doublet chemotherapy
• Or within 12 weeks after last dose of anti-PD-1/PD-L1 blockingantibody

3. Participants who have an Eastern Cooperative Oncology Group (ECOG) performancestatus of 0 or 1.

4. Participants who is assessed as having at least one resectable lesion.

5. Participants who have at least one measurable lesion, following resection of thelesion for IOV-4001 generation.

6. Participants who have adequate organ function.

7. Cardiac function test required.

8. Pulmonary function test may be required.

9. Participants of childbearing potential or those with partners of childbearingpotential must be willing to practice an approved method of highly effective birthcontrol during treatment and up to 12 months.

10. Participants who are >70 years of age may be allowed to enroll after theinvestigator discusses with the medical monitor.

Exclusion Criteria:

1. Participants who have melanoma of uveal/ocular origin.

2. Participants who have symptomatic untreated brain metastases.

3. Participants who have had a history of allogeneic organ transplant or any form ofcell therapy involving prior conditioning chemotherapy within the past 20 years.

4. Participants who require systemic steroid therapy 10 mg/day prednisone or anothersteroid equivalent dose.

5. Participants who have any form of primary immunodeficiency.

6. Participants who have another primary malignancy within the previous 3 years.

7. Participants who have received or will receive a live or attenuated vaccinationwithin 28 days prior to the start of the NMA-LD.